Using biomedical big data to explore the genetic markers and clinical prognosis of gastric cancer

[[abstract]]根據世界衛生組織統計，胃癌在全世界的排名是第四個普遍被診斷的癌症，然後癌症的死亡率也是排名第二高，已經被視為重要的健康危害。胃癌的發病機制仍未完全表徵，可靠的分子生物標誌物數量有限，目前在臨床實踐中是有針對性的。所以急需全面性探討基因組，以期找到胃癌生物標誌物，進而應用於早期診斷、預後預測和潛在治療標靶點。為解決上述問題，我們全面性分析胃癌患者與正常人之基因體各項實驗數據，結合基因表現量、基因突變率以及臨床資料，以期發現胃癌之預後標誌物。本研究我們透過NCBI-GEO進行stomach GPL570(生物晶片)實驗數據資料庫統整，搜尋胃癌相關實驗數據，分析差異表現基因共有54個基因，接著進行功能分析、突變率分析、臨床預後分析。結果發現，有12個基因(EPHB2、COL12A1、ASPM、GJB2、KPNA2、S100A10、PTPN12、WDR72、TRPA1、SLC4A4、GLUL、AXDND1)預後生存圖具有明顯差異，其中TRPA1、ASPM、EPHB2基因至少具有2倍差異基因表現，並且呈現正向預後趨勢，我們的結果與文獻相似。而GLUL基因在本研究之預後分析，雖具統計意義（p-valu=0.0193）呈現正向預後，但存活月份差異不明顯，推論可能是病例數不足，該基因沒有找到與胃癌之相關文獻。為進一步觀察上述基因之間是否存在加乘效益，我們將其合併，觀察其臨床預後，結果顯示合併TRPA1、EPHB2、GLUL、ASPM四個基因在胃癌具有正向之預後，平均存活率提高三倍。經過我們一系列生物資訊探戡，發現TRPA1、EPHB2、GLUL、ASPM在胃癌均具有正向預後顯著，且合併後，更可提高其預後平均存活率，綜上所述TRPA1、EphB2、GLUL、ASPM可作為預測胃癌的預後指標。[[abstract]]According to estimates by the World Health Organization，gastric cancer is the fourth According to the statistics of the World Health Organization, gastric cancer ranks the fourth most commonly diagnosed cancer in the world, and the death rate of cancer is also ranked second, and has been regarded as an important health hazard. The pathogenesis of gastric cancer has not yet been fully characterized, and the number of reliable molecular biomarkers is limited, and they are currently targeted in clinical practice. Therefore, it is urgent to comprehensively explore the genome in order to find gastric cancer biomarkers, and then apply them to early diagnosis, prognosis prediction and potential treatment targets. In order to solve the above problems, we comprehensively analyze the experimental data of the genomic body of gastric cancer patients and normal people, combined with gene expression, gene mutation rate and clinical data, with a view to discovering prognostic markers of gastric cancer.In this study, we used NCBI-GEO to integrate the stomach GPL570 (biochip) experimental data database, search for gastric cancer-related experimental data, analyze a total of 54 genes for differentially expressed genes, and then perform functional analysis, mutation rate analysis, and clinical prognosis analysis. The results showed that there are 12 genes (EPHB2, COL12A1, ASPM, GJB2, KPNA2, S100A10, PTPN12, WDR72, TRPA1, SLC4A4, GLUL, ADXND1) with significant differences in prognostic survival maps, of which TRPA1, ASPM, EPHB2 genes have at least 2 times Different gene performance, and showing a positive prognostic trend, our results are similar to those in the literature. In the prognostic analysis of the GLUL gene in this study, although it is statistically significant (p-valu=0.0193), it presents a positive prognosis, but the difference in survival months is not obvious. The inference may be that the number of cases is insufficient. The gene has not found relevant literature on gastric cancer. In order to further observe whether there is a multiplicative benefit between the above genes, we combined them and observed their clinical prognosis. The results showed that the combination of TRPA1, EPHB2, GLUL, and ASPM has a positive prognosis in gastric cancer, and the average survival rate is increased by three times.After a series of biological information explorations, we found that TRPA1, EPHB2, GLUL, and ASPM all have significant positive prognosis in gastric cancer, and the combination can increase the average prognostic survival rate. In summary, TRPA1, EphB2, GLUL, ASPM It can be used as a prognostic indicator for predicting gastric cancer